Shots:
- Bayer has reported post-hoc analyses from P-III (ARANOTE) trial assessing Nubeqa (darolutamide; 600mg, BID) + androgen deprivation therapy (ADT) (n=446) vs PBO + ADT (n=223) in mHSPC pts (N=669)
- Post-hoc analyses showed that 42.6% pts achieved ultra-low PSA levels (<0.02ng/mL) vs 7.8% pts on PBO & this response was associated with prolonged rPFS, delayed time to mCRPC, & reduced PSA progression; data was presented at AUA 2025
- Previously reported initial data showed improved rPFS (1EP), with 46% reduction in the risk of radiologic progression or death compared to PBO + ADT; data was presented at ESMO 2024 & published in The JCO
Ref: Businesswire | Image: Bayer
Related News:- Bayer’s Vitrakvi Receives the US FDA’s Full Approval for NTRK Fusion-Positive Solid Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
